Eppendorf Centrifuge 5920 R: the new benchmark in capacity and performance
Also offers a powerful state-of-the-art refrigeration system with advanced temperature management.
Eppendorf’s new refrigerated Centrifuge 5920 R combines extraordinary high capacity with enhanced temperature management in a very compact and ergonomic product design.
Centrifuge 5920 R can accommodate up to 4 x standard 1 Liter Nalgene bottles, as well as up to 108 x 15 mL conical tubes, and 52 x 50 mL conical tubes, enabling researchers to spin large volumes at any one time, in applications such as bioprocessing or cell culture. Additionally, the universal rotor bucket design means researchers can spin both plates and tubes in the same bucket without the need to purchase separate plate buckets.
Eppendorf’s Centrifuge 5920 R also offers a powerful state-of-the-art refrigeration system with advanced temperature management, meaning users can be confident that their temperature-sensitive samples are safe. Dynamic compressor control technology and a FastTemp pro function also allows precise and automated pre-cooling based on a pre-programmable time and date.
Easy to use, the Centrifuge 5920 R features a multi-lingual menu with backlit display with 5 program keys enabling rapid access to routine programs, as well as an adjustable ECO shut-off function to save energy and increase compressor life. “With laboratories under increasing pressure to increase efficiencies and throughput we understand the challenges that researchers face in their work,” said Peter Schreiner, Global Product Manager Centrifugation at Eppendorf. “The very large capacity and precise temperature management offered by the Centrifuge 5920 R means researchers can be assured that not only are their samples safe, but that they are saving time, money and energy with this system.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...